Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap

About this update from Citius Pharmaceuticals, Inc.

[{"type":"text","content":"Expansion of patents granted to The University of Texas System on behalf of M. D. Anderson Cancer Center\n\n\nCRANFORD, N.J., Aug. 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced that it has expanded the intellectual property associated with its global license agreement with the MD Anderson Cancer Center (\"MDACC\"). Through this license agreement, Citius is developing Mino-Wrap, which is a novel approach to reducing post-mastectomy infections associated with the use of a tissue expander (\"TE\").\nThe United States Patent and Trademark Office (USPTO) has issued patent 10,434,221 B2 and patent application publication US 2019/0388591 A1, both continuations of the initial patent for \"Antimicrobial Wraps for Medical Implants\". \nThe intellectual property expansion was granted to The Board of Regents of The University of Texas System on behalf of The University of Texas M. D. Anderson Cancer Center and enhances the design and use of Mino-Wrap. \n\"The frequency of post-mastectomy breast reconstruction, following breast cancer treatment, has been increasing on an annual basis. There are over 100,000 patients in the U.S. undergoing breast reconstruction procedures following mastectomies and approximately 80% of the time, a TE is used to prepare the surgical site for breast implants either immediately after mastectomy or in a separate procedure afterwards. The published rate of infection for TEs used in breast reconstructive surgery is between 2.5 % and 24%, with an estimated mean at around 12% to 14%. These data points are concerning and not well understood. Through our agreement with MDACC, we believe Mino-Wrap has the potential to provide a significant reduction in the incidence of infection, sparing the patient the pain and discomfort of extended hospitalization and further aggressive and lengthy courses of antibiotics in an attempt to salvage the TEs. In many cases the TE is removed leading to a delay in lifesaving chemo-radiation therapy, which can be a devastating consequence for the patient. \" said Myron Holubiak, President and CEO of Citius Pharmaceuticals. \"We are especially pleased that the claims for Mino-Wrap intellectual property are being expanded an...

More updates from Citius Pharmaceuticals, Inc.